180 Wealth Advisors’s Ginkgo Bioworks DNA Stock Holding History

180 Wealth Advisors’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-545	Closed	-$6.98K	–	451
2024 Q2	$6.98K	Sell	545 -96	-15%	-$2.86K	﹤0.01%	434
2024 Q1	$29.7K	Buy	641 +4	+0.6%	+$207	0.01%	402
2023 Q4	$42.6K	Sell	637 -42	-6%	-$2.57K	0.01%	380
2023 Q3	$49.2K	Buy	679 +5	+0.7%	+$400	0.01%	368
2023 Q2	$48K	Sell	674 -68	-9%	-$4.03K	0.01%	362
2023 Q1	$39.5K	Hold	742	–	–	0.01%	362
2022 Q4	$51.9K	Buy	742 +28	+4%	+$2.58K	0.01%	363
2022 Q3	$89K	Sell	714 -38	-5%	-$4.53K	0.02%	344
2022 Q2	$72K	Buy	752 +93	+14%	+$11.3K	0.02%	359
2022 Q1	$101K	Buy	659 +343	+109%	+$66.8K	0.02%	365
2021 Q4	$67K	Buy	+316	New	+$150K	0.02%	369

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

180 Wealth Advisors's DNA Position: Q3 2024 in Review

180 Wealth Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 545 shares — an estimated $6.98K sold.

180 Wealth Advisors first reported a position in DNA in Q4 2021 and held it in 11 quarters. The position peaked at $101K in Q1 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

180 Wealth Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
180 Wealth Advisors sold 545 Ginkgo Bioworks shares in Q3 2024, an estimated $6.98K.
180 Wealth Advisors first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 11 quarters.
180 Wealth Advisors's Ginkgo Bioworks position peaked at $101K in Q1 2022.
159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on 180 Wealth Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.